Page last updated: 2024-12-04

amosulalol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

amosulalol: RN given is for mono-HCl; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2169
CHEMBL ID152231
CHEBI ID135592
SCHEMBL ID48933
MeSH IDM0101358

Synonyms (30)

Synonym
5-(1-hydroxy-2-((2-(2-methoxyphenoxy)ethyl)amino)ethyl)-2-methylbenzenesulfonamide
amosulalol
D07451
85320-68-9
amosulalol (inn)
(+-)-5-(1-hydroxy-2-((2-(o-methoxyphenoxy)ethyl)amino)ethyl)-o-toluenesulfonamide
amosulalol [inn]
amosulalolum [latin]
CHEBI:135592
CHEMBL152231
L001814
5-[1-hydroxy-2-[2-(2-methoxyphenoxy)ethylamino]ethyl]-2-methylbenzenesulfonamide
cas_93633-92-2
bdbm81882
amosulalolum
c69ji1bau8 ,
unii-c69ji1bau8
amosulalol [who-dd]
(+/-)-5-(1-hydroxy-2-((2-(o-methoxyphenoxy)ethyl)amino)ethyl)-o-toluenesulfonamide
amosulalol [mi]
SCHEMBL48933
5-{1-hydroxy-2-[2-(2-methoxyphenoxy)ethylamino]-ethyl}-2-methylbenzenesulfonamide
LVEXHFZHOIWIIP-UHFFFAOYSA-N
5-[1-hydroxy-2-[[2-(2-methoxyphenoxy)ethyl]amino]ethyl]-2-methylbenzenesulfonamide
AKOS030530805
Q4747983
FT-0767977
DTXSID90868893
CS-0026410
HY-106720

Research Excerpts

Overview

Amosulalol is an antihypertensive drug with selective postsynaptic alpha 1 and non-selective beta blocking effects.

ExcerptReferenceRelevance
"Amosulalol is an antihypertensive drug with selective postsynaptic alpha 1 and non-selective beta blocking effects. "( Determination of amosulalol in human plasma using solid-phase extraction combined with liquid chromatography and ultraviolet detection.
Chun, IK; Gwak, HS; Lee, NY; Noh, ES, 2005
)
2.11

Treatment

ExcerptReferenceRelevance
"Pretreatment with amosulalol, particularly at a dose of 0.3 mg.kg-1, reduced the myocardial energy depletion and the alteration of carbohydrate metabolism induced by ischemia."( Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs.
Chiba, K; Hayase, N; Ichihara, K, 1993
)
1

Pharmacokinetics

ExcerptReferenceRelevance
" After repeated oral administration (10 mg/kg) to dogs for 15 days, the pharmacokinetic parameters did not differ significantly from those on the first day."( Pharmacokinetics of amosulalol, an alpha, beta-adrenoceptor blocker, in rats, dogs and monkeys.
Kamimura, H; Kawamura, S; Sasaki, H, 1984
)
0.59

Bioavailability

ExcerptReferenceRelevance
" These results suggest that amosulalol is well absorbed and is little affected by first-pass metabolism."( Amosulalol, a combined alpha and beta adrenoceptor antagonist: kinetics after intravenous and oral doses.
Asano, M; Hashimoto, H; Miyazaki, M; Nakashima, M; Ohguchi, S; Seki, T; Takenaka, T, 1984
)
2
" The systemic bioavailability of a 10-mg/kg dose was 38."( Pharmacokinetics and metabolism of an alpha,beta-blocker, amosulalol hydrochloride, in mice: biliary excretion of carbamoyl glucuronide.
Kamimura, H; Suzuki, K, 2007
)
0.58

Dosage Studied

ExcerptRelevanceReference
"In the isolated guinea-pig right atria and tracheal strips, both propranolol and YM-09538 caused a parallel shift of the dose-response curve for isoproterenol to the right, indicating that these two drugs block nonselectively the beta 1 1- and beta 2-adrenoceptors."( Comparison of airway obstruction induced by propranolol and YM-09538 (a combined alpha- and beta-adrenoceptor blocking drug).
Takenaka, T; Tomioka, K; Yamada, T, 1982
)
0.26
" The biliary excretion after oral dosage amounted to 66% and 41% in rats and dogs, respectively."( Disposition and metabolism of amosulalol hydrochloride, a new combined alpha- and beta-adrenoceptor blocking agent, in rats, dogs and monkeys.
Kamimura, H; Kaniwa, H; Kawamura, S; Sasaki, H; Takaichi, M; Yokoshima, T, 1984
)
0.56
" Plasma levels of amosulalol after intravenous dosing declined biphasically and fitted a two-compartment model."( Amosulalol, a combined alpha and beta adrenoceptor antagonist: kinetics after intravenous and oral doses.
Asano, M; Hashimoto, H; Miyazaki, M; Nakashima, M; Ohguchi, S; Seki, T; Takenaka, T, 1984
)
2.04
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-199024 (63.16)18.7374
1990's11 (28.95)18.2507
2000's3 (7.89)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.70 (24.57)
Research Supply Index3.66 (2.92)
Research Growth Index4.07 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.63%)6.00%
Case Studies4 (10.53%)4.05%
Observational0 (0.00%)0.25%
Other33 (86.84%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]